Do analysts recommend MGRX or DCGO?

DocGo has a consensus target price of $2.38, indicating a potential upside of 542.76%. Given DocGo's stronger consensus rating and higher probable upside, analysts plainly believe DocGo is more favorable than Mangoceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is MGRX or DCGO more profitable?

DocGo has a net margin of -65.29% compared to Mangoceuticals' net margin of -4,794.60%. DocGo's return on equity of -40.42% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mangoceuticals -4,794.60% -96.39% -89.60% DocGo -65.29% -40.42% -24.81%

Does the media favor MGRX or DCGO?

In the previous week, Mangoceuticals and Mangoceuticals both had 5 articles in the media. Mangoceuticals' average media sentiment score of 1.26 beat DocGo's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mangoceuticals 2 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DocGo 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RYOJ or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYOJ 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, RYOJ or MGRX?

RYOJ has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYOJ $9.34M 3.52 $120K N/A N/A Mangoceuticals $460K 20.50 -$20.64M -$1.01 N/A

Is RYOJ or MGRX more profitable?

RYOJ has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. RYOJ's return on equity of 0.00% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets RYOJ N/A N/A N/A Mangoceuticals -4,794.60% -96.39% -89.60%

Do analysts prefer GXAI or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GXAI or MGRX more profitable?

Gaxos.ai has a net margin of -64.81% compared to Mangoceuticals' net margin of -4,794.60%. Gaxos.ai's return on equity of -38.79% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Gaxos.ai -64.81% -38.79% -36.99% Mangoceuticals -4,794.60% -96.39% -89.60%

Does the media favor GXAI or MGRX?

In the previous week, Mangoceuticals had 3 more articles in the media than Gaxos.ai. MarketBeat recorded 5 mentions for Mangoceuticals and 2 mentions for Gaxos.ai. Mangoceuticals' average media sentiment score of 1.26 beat Gaxos.ai's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gaxos.ai 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mangoceuticals 2 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MGRX or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, MGRX or BMGL?

Basel Medical Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mangoceuticals $460K 20.50 -$20.64M -$1.01 N/A Basel Medical Group $8.90M 0.58 -$9.50M N/A N/A

Do analysts rate AIDX or MGRX?

20/20 Biolabs presently has a consensus price target of $5.00, indicating a potential upside of 1,215.79%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, equities research analysts clearly believe 20/20 Biolabs is more favorable than Mangoceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to AIDX or MGRX?

In the previous week, Mangoceuticals had 2 more articles in the media than 20/20 Biolabs. MarketBeat recorded 5 mentions for Mangoceuticals and 3 mentions for 20/20 Biolabs. Mangoceuticals' average media sentiment score of 1.26 beat 20/20 Biolabs' score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 20/20 Biolabs 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mangoceuticals 2 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mangoceuticals (MGRX) Competitors

$0.44 -0.04 (-9.03%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.42 -0.02 (-3.91%)

As of 10/2/2026 07:37 PM Eastern

Compare

MGRX vs. DCGO, RYOJ, GXAI, BMGL, and AIDX

Should you buy Mangoceuticals stock or one of its competitors? Mangoceuticals's main competitors and comparable companies include DocGo (DCGO), RYOJ (RYOJ), Gaxos.ai (GXAI), Basel Medical Group (BMGL), and 20/20 Biolabs (AIDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Mangoceuticals compare to DocGo?

Mangoceuticals (NASDAQ:MGRX) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

DocGo has a net margin of -65.29% compared to Mangoceuticals' net margin of -4,794.60%. DocGo's return on equity of -40.42% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
DocGo	-65.29%	-40.42%	-24.81%

DocGo has a consensus target price of $2.38, indicating a potential upside of 542.76%. Given DocGo's stronger consensus rating and higher probable upside, analysts plainly believe DocGo is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by company insiders. Comparatively, 5.1% of DocGo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Mangoceuticals has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market. Comparatively, DocGo has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Mangoceuticals has higher earnings, but lower revenue than DocGo. Mangoceuticals is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	20.50	-$20.64M	-$1.01	N/A
DocGo	$322.20M	0.11	-$182.40M	-$1.96	N/A

In the previous week, Mangoceuticals and Mangoceuticals both had 5 articles in the media. Mangoceuticals' average media sentiment score of 1.26 beat DocGo's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mangoceuticals	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

DocGo beats Mangoceuticals on 8 of the 15 factors compared between the two stocks.

How does Mangoceuticals compare to RYOJ?

RYOJ (NASDAQ:RYOJ) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

RYOJ has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYOJ	$9.34M	3.52	$120K	N/A	N/A
Mangoceuticals	$460K	20.50	-$20.64M	-$1.01	N/A

In the previous week, Mangoceuticals had 5 more articles in the media than RYOJ. MarketBeat recorded 5 mentions for Mangoceuticals and 0 mentions for RYOJ. Mangoceuticals' average media sentiment score of 1.26 beat RYOJ's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
RYOJ	Neutral
Mangoceuticals	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYOJ	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

RYOJ has a beta of 4.54, meaning that its stock price is 354% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

RYOJ has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. RYOJ's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYOJ	N/A	N/A	N/A
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

56.7% of Mangoceuticals shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

RYOJ beats Mangoceuticals on 6 of the 11 factors compared between the two stocks.

How does Mangoceuticals compare to Gaxos.ai?

Gaxos.ai (NASDAQ:GXAI) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

In the previous week, Mangoceuticals had 3 more articles in the media than Gaxos.ai. MarketBeat recorded 5 mentions for Mangoceuticals and 2 mentions for Gaxos.ai. Mangoceuticals' average media sentiment score of 1.26 beat Gaxos.ai's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gaxos.ai	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mangoceuticals	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

42.6% of Gaxos.ai shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Gaxos.ai has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market.

Gaxos.ai has a net margin of -64.81% compared to Mangoceuticals' net margin of -4,794.60%. Gaxos.ai's return on equity of -38.79% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gaxos.ai	-64.81%	-38.79%	-36.99%
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

Gaxos.ai has higher revenue and earnings than Mangoceuticals. Gaxos.ai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gaxos.ai	$1.93M	2.87	-$3.90M	-$0.50	N/A
Mangoceuticals	$460K	20.50	-$20.64M	-$1.01	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Mangoceuticals beats Gaxos.ai on 7 of the 13 factors compared between the two stocks.

How does Mangoceuticals compare to Basel Medical Group?

Mangoceuticals (NASDAQ:MGRX) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Basel Medical Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. Basel Medical Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
Basel Medical Group	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

56.7% of Mangoceuticals shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Mangoceuticals had 5 more articles in the media than Basel Medical Group. MarketBeat recorded 5 mentions for Mangoceuticals and 0 mentions for Basel Medical Group. Mangoceuticals' average media sentiment score of 1.26 beat Basel Medical Group's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Mangoceuticals	Positive
Basel Medical Group	Neutral

Basel Medical Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	20.50	-$20.64M	-$1.01	N/A
Basel Medical Group	$8.90M	0.58	-$9.50M	N/A	N/A

Mangoceuticals has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Summary

Mangoceuticals beats Basel Medical Group on 6 of the 11 factors compared between the two stocks.

How does Mangoceuticals compare to 20/20 Biolabs?

20/20 Biolabs (NASDAQ:AIDX) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

In the previous week, Mangoceuticals had 2 more articles in the media than 20/20 Biolabs. MarketBeat recorded 5 mentions for Mangoceuticals and 3 mentions for 20/20 Biolabs. Mangoceuticals' average media sentiment score of 1.26 beat 20/20 Biolabs' score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
20/20 Biolabs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mangoceuticals	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

20/20 Biolabs presently has a consensus price target of $5.00, indicating a potential upside of 1,215.79%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, equities research analysts clearly believe 20/20 Biolabs is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

56.7% of Mangoceuticals shares are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by company insiders. Comparatively, 16.0% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

20/20 Biolabs has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. 20/20 Biolabs' return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

20/20 Biolabs has higher revenue and earnings than Mangoceuticals. 20/20 Biolabs is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.04M	2.38	-$3.74M	-$0.54	N/A
Mangoceuticals	$460K	20.50	-$20.64M	-$1.01	N/A

Summary

20/20 Biolabs beats Mangoceuticals on 10 of the 15 factors compared between the two stocks.

Get Mangoceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGRX vs. The Competition

Export

Metric	Mangoceuticals	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.43M	$9.59B	$7.14B	$13.18B
Dividend Yield	N/A	2.61%	2.53%	16.78%
P/E Ratio	-0.43	34.21	275.68	26.04
Price / Sales	29.91	5.44	663.82	108.79
Price / Cash	N/A	120.59	77.60	51.75
Price / Book	0.47	5.15	10.93	6.31
Net Income	-$20.64M	$315.68M	$3.51B	$362.16M
7 Day Performance	-6.20%	-2.59%	-2.00%	-1.66%
1 Month Performance	11.99%	-3.19%	-6.15%	-4.50%
1 Year Performance	-80.74%	7.93%	7.44%	2.06%

Mangoceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGRX Mangoceuticals	1.4319 of 5 stars	$0.44 -9.0%	N/A	-80.0%	$9.43M	$315.23K	N/A	3	News Coverage Positive News Gap Down
DCGO DocGo	2.1732 of 5 stars	$0.38 -4.1%	$2.38 +528.3%	-71.1%	$37.59M	$322.20M	N/A	3,568	News Coverage Analyst Forecast
RYOJ RYOJ	N/A	$3.03 flat	N/A	N/A	$35.00M	$9.34M	N/A	N/A
GXAI Gaxos.ai	0.2546 of 5 stars	$0.52 -2.3%	N/A	-70.2%	$5.57M	$1.93M	N/A	3	News Coverage
BMGL Basel Medical Group	N/A	$3.35 +10.9%	N/A	-83.3%	$5.29M	$8.90M	N/A	70	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGRX) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mangoceuticals (MGRX) Competitors

MGRX vs. DCGO, RYOJ, GXAI, BMGL, and AIDX

How does Mangoceuticals compare to DocGo?

Summary

How does Mangoceuticals compare to RYOJ?

Summary

How does Mangoceuticals compare to Gaxos.ai?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Summary

How does Mangoceuticals compare to 20/20 Biolabs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mangoceuticals (MGRX) Competitors

MGRX vs. DCGO, RYOJ, GXAI, BMGL, and AIDX

How does Mangoceuticals compare to DocGo?

Is MGRX or DCGO more profitable?

Do analysts recommend MGRX or DCGO?

Do insiders and institutionals have more ownership in MGRX or DCGO?

Which has more volatility and risk, MGRX or DCGO?

Which has better earnings & valuation, MGRX or DCGO?

Does the media favor MGRX or DCGO?

Summary

How does Mangoceuticals compare to RYOJ?

Which has preferable earnings & valuation, RYOJ or MGRX?

Does the media favor RYOJ or MGRX?

Do analysts recommend RYOJ or MGRX?

Which has more volatility & risk, RYOJ or MGRX?

Is RYOJ or MGRX more profitable?

Do institutionals and insiders hold more shares of RYOJ or MGRX?

Summary

How does Mangoceuticals compare to Gaxos.ai?

Does the media favor GXAI or MGRX?

Do insiders and institutionals hold more shares of GXAI or MGRX?

Which has more volatility and risk, GXAI or MGRX?

Is GXAI or MGRX more profitable?

Which has stronger valuation & earnings, GXAI or MGRX?

Do analysts prefer GXAI or MGRX?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Is MGRX or BMGL more profitable?

Do analysts rate MGRX or BMGL?

Do insiders & institutionals believe in MGRX or BMGL?

Does the media refer more to MGRX or BMGL?

Which has higher earnings & valuation, MGRX or BMGL?

Which has more risk and volatility, MGRX or BMGL?

Summary

How does Mangoceuticals compare to 20/20 Biolabs?

Does the media refer more to AIDX or MGRX?

Do analysts rate AIDX or MGRX?

Do insiders and institutionals have more ownership in AIDX or MGRX?

Is AIDX or MGRX more profitable?

Which has higher valuation and earnings, AIDX or MGRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools